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Abstract
THE EFFECT OF CHRONIC CONSTRICTION INJURY ON CELLULAR SYSTEMS
WITHIN NOCICEPTIVE PATHWAYS IN THE MOUSE
By Michelle R. Hoot, B.S.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Dr. William L. Dewey
Professor, Interim Chair, Pharmacology and Toxicology

Chronic neuropathic pain is often difficult to treat due to its resistance to therapeutic
intervention. This is due in part to the poor understanding of the physiological
mechanisms involved in the establishment and maintenance of neuropathic pain states. The
neuropathic pain model, chronic constriction injury of the sciatic nerve, produced robust
pain hypersensitivity in our mice. It also induced significant changes in the mitogen
activated protein kinase family, and the cannabinoid and µ-opioid systems in three
different brain areas involved in the modulation or regulation of pain states.

CCI induced a 2.5 fold increase in mRNA of the kinase Raf-1 in the PAG of mice. Raf-1 is
part of the ERK cascade in the MAP kinase family of proteins. The MAPK family of
proteins has previously been shown to be involved in the establishment and maintenance of
chronic neuropathic pain via central sensitization and the PAG is a critical regulator of
nociceptive input and is part of the descending pain pathway, which has also been shown
to have a role in central sensitization.

x

CCI also resulted in significant decreases in the µ-opioid receptor agonist DAMGO
stimulated [35S] GTPγS binding in the medial thalamus, and the cannabinoid receptor
agonist, WIN 55, 212-2 stimulated [35S] GTPγS binding in the anterior cingulate cortex.
These effects were not due to an overall decrease in µ-opioid receptor or cannabinoid
receptor 1 binding, suggesting that the chronic pain-like condition resulted in a
desensitization of these receptors. Both the medial thalamus and the anterior cingulate
cortex are brain areas involved in the medial pain pathway which, along with the limbic
system, have been shown to be involved in the affective component of pain processing.

These data are the first to demonstrate changes in these three cellular systems in the
respective brain areas of the mouse in response to chronic neuropathic pain. The novel
findings presented in this dissertation provide new areas of investigation for the treatment
of this debilitating disease.
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Chapter I
Introduction
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Introduction
Severe and chronic pain are debilitating conditions and an issue of such importance that
U.S. Congress passed legislation (H.R. 3244) that was signed into law declaring 20002010 as the “Decade of Pain Control and Research”. This is understandable when
viewed from the perspective that 75 million Americans suffer from severe pain each year
and 50 million of those people report their pain condition as being chronic (Berry, 2006).
From a financial perspective, severe and chronic pain accounts for 150 billion US dollars
in healthcare costs and 50 million lost work days per year (Berry, 2001;Turk, 2002). This
type of loss is shouldered not only by patients and their families but by society as a
whole. When taken into consideration that those over 65 years old suffer from severe and
chronic pain ten times more often than those under the age of 30 (Stanford Medical
Center, 2005), the cost of chronic pain is bound to grow significantly in the coming
decade as the baby-boomer generation ages into their retirement years.

One may wonder why something like pain could cause such an enormous social and
financial toll on society. Surveys of chronic pain sufferers shed some light on this issue.
The issue does not rest in patients avoiding health care professionals; in fact 92% of
patients have seen a healthcare professional about their pain (Association, 2004). Most
pain sufferers seek treatment for their pain and the most common treatments are
pharmacological, with non-sterioidal anti- inflammatory drugs (NSAIDs) and opioids
being the most commonly used. NSAIDs are the most commonly utilized class of drugs
due to the low cost and over the counter availability but only 12% of chronic pain
sufferers report them working “very well” (Stanford Medical Center, 2005). Opioids are
widely considered the most effective way to combat severe pain due to their direct central
nervous effects and thus many chronic pain patients use them on a daily basis. However,
only 23% of chronic pain sufferers rated opioids as “very effective” in treating their pain
and almost 10% rated them as “ineffective”. In addition, 51% of opioid users report
having “only a little” or “no control” over their pain (Michaelson & Company, 2006).
These statistics are disconcerting as this type of uncontrollable suffering can lead to
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significantly lower quality of life that may cause comorbid psychological illness. In fact,
a survey conducted by the American Chronic Pain Association (2004) found that 46% of
chronic pain patients reported experiencing depression and 35% percent expressed
feelings of the “inability to cope” as a result of their pain. Clearly the conventional
treatments for chronic pain are lacking at best and chronic, uncontrollable pain can lead
to potentially serious psychological illness which can lead to even greater healthcare
costs and lost productivity. Therefore, alternative treatments are not only necessary from
a humanitarian standpoint but also from a financial and societal perspective.
What Is Pain?
According to the International Association for the Study of Pain (IASP), pain is “an
unpleasant sensory and emotional experience associated with actual or potential tissue
damage, or described in terms of such damage.” This definition speaks to the subjective
nature of pain, and essentially, the experience of pain is unique to each individual. Pain
is however, different from nociception in that nociception arises from the direct
activation of nociceptor in either internal or external tissue. Nociceptor stimulation does
not necessarily lead to the experience of pain, and pain is not necessarily caused by direct
stimulation of nociceptors. Herein lies the difference between what is thought of as acute
pain and chronic pain. Acute pain is a necessary component to the survival of an
organism because it lets it know when noxious stimulation has occurred and helps an
organism avoid further injury. It usually has a direct correlate to some type of tissue
injury and nociceptor activation. Chronic pain, on the other hand, is defined not only by
time course, but as “pain that extends beyond normal period of healing, disrupts sleep and
normal living, ceases to serve a protective function, and instead degrades health and
functional capability” (Berry, 2006).
Chronic pain can present itself in many ways and the most often studied are neuropathic
and inflammatory pain. Neuropathic pain is caused by damage to or dysfunction of any
part of the somatosensory system of the central nervous system (CNS). It can be caused
by a variety of different events including peripheral nerve trauma, diabetes, multiple
sclerosis, and CNS damage from stroke or viral infections. Clinically, neuropathic pain is
characterized by multiple symptomologies. Symptoms commonly seen in humans are
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motor weakness, numbness, and deficits or absence in deep tendon reflexes in the injured
area (Gilron et al., 2006) as well as hyperalgesia, allodynia and stimulus-independent
pain (Jensen et al., 2001). Hyperalgesia is classified as an “increased response to a
stimulus which is normally painful” and allodynia is classified as “pain due to a stimulus
which does not normally evoke pain” which, unlike hyperalgesia, “indicates loss of
specificity of a sensory modality” (IASP, 1994). Stimulus independent-pain is
spontaneous pain without an externally evoked stimulus. Hyperalgesia, allodynia, and
stimulus-independent pain are considered the three “classic” signs of chronic pain and in
both clinical and animal research are often used to obtain quantitative measures of the
presence and intensity of chronic pain.
Chronic inflammatory pain includes the common conditions of rheumatoid arthritis and
in many cases back pain and some types of visceral pain that arise from irritable bowel
disease. It is characterized by two zones, the first being the zone of `primary'
hyperalgesia, which encompasses the area of tissue damage itself and is characterized by
spontaneous pain hypersensitivity to thermal, mechanical and chemical stimuli. The zone
of `secondary' hyperalgesia does not include any tissue damage but displays
hypersensitivity to mechanical but not thermal stimuli. (Millan, 1999)
Physiologically speaking, pain arises from the activation of mechanical, thermal or
polymodal nociceptors. Unlike receptors that mediate non-noxious touch and pressure,
nociceptors do not have specialized receptors but instead are located on free nerve
endings within the skin or viscera. Mechanical and thermal nociceptors have thinly
myelinated Aδ fibers that mediate fast, sharp pain while polymodal nociceptors have
unmyelinated C fibers which are responsible for the conduction of pain that is described
as slow, dull or burning (Kandel, 2000). The cell bodies of the nociceptive neurons are
located within the dorsal root ganglion and are pseudo-unipolar neurons. Their afferents
terminate in neurons in the dorsal horn of the spinal cord, and depending upon which
lamina afferents terminate in, ascend through the spinal cord via one of several ascending
pathways.
The spinothalamic tract is the main ascending tract that delivers information about the
sensation of pain and is divided into two main branches, the medial and lateral
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spinothalamic tracts. The lateral spinothalamic tract originates in both lamina I and V of
the spinal cord and ascends contralaterally into the brainstem and synapses in the lateral
nuclei of the thalamus and then into the primary and secondary somatosensory corticies
(Figure 1). This part of the spinothalamic tract encodes for the sensory-discriminative
aspect of pain which provides information such as localization and quality of a painful
stimulus. The medial aspect of the spinothalamic tract originates primarily in lamina I
and deep lamina of the spinal cord. It ascends contralaterally into the medial nuclei of the
thalamus and then into the anterior and insular cortices which then project to the
prefrontal cortex (Figure 2). The medial aspect of the spinal thalamic tract is responsible
for encoding the affective-motivational aspect of pain. The affective-motivational
component of pain is what is considered to be the emotional experience of “suffering”
from pain as well as the desire to avoid and eliminate the painful experience. The
differences in the two systems are highlighted within patients suffering from the
condition pain asymbolia. Pain asymbolia patients show lesions to the medial pain
pathway structure of the insular cortex and thus have deficits in the affective component
of pain processing. These patients are able to accurately detect and locate painful stimuli
and will even describe it as painful. However, they do not demonstrate withdrawal
movements or express negative emotional responses to the stimuli. In fact, some of these
patients were reported to smile and laugh at the painful stimulation (Berthier et al., 1988).
On the other hand, the descending pain pathways are responsible for modulation of pain
processing. The most studied descending pain pathway originates in the periaqueductal
grey (PAG) and descends through the rostroventral medial medulla (RVMM) to regulate
the release of proinflammatory mediators in the dorsal horn of the spinal cord via
inhibitory mechanisms. Interestingly, this system is also responsible for what is termed
“descending facilitation” which is the potentiation of nociceptive neuronal responses in
the spinal cord. It is hypothesized that the seemingly dichotomous function of the
descending pain pathway is due to the release of many different types of
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Figure 1: The Lateral Spinothalamic Tract
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Figure 1: The lateral spinothalamic pain pathway, which transmits and processes
information about the sensory-discriminative aspects of pain. SI, primary somatosensory
cortex ; SII, secondary somatosensory cortex; VPI, ventral posterior inferior nucleus ;
VPL ventral posterior lateral nucleus ; VPM ventral posterior medial nucleus. Adapted
from Treede et al.,(1999).
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Figure 2: The Medial Spinothalamic Tract
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Figure 2: The medial spinothalamic tract which is involved in the affective-motivational
component of pain processing. ACC, anterior cingulate cortex; MDvc, ventrocaudal part
of the medial dorsal nucleus; nPf, parafascicular nucleus; PFC, prefrontal cortex; VMpo,
posterior part of ventromedial nucleus. Adapted from Treede et. al, (1999).
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neurotransmitters, which like in the case of serotonin, can be either inhibitory or
excitatory depending upon which particular receptor subtype is activated (Millan, 2002).
Chronic Pain Models
To study the effects of chronic pain numerous animal models have been developed to
mimic the various disease and traumatic states which can lead to chronic pain conditions
in humans. These models induce chronic pain by causing either local or systemic
inflammatory reactions in the animal or by causing trauma to various parts of the nervous
system. There are a several chronic inflammatory models but the most well established
and most often used model is the complete Freund’s adjuvant (CFA) model of arthritis.
This model involves the injection of heat deactivated Mycobacterium butyricum
subcutaneously into the base of the tail or hind-paw. While this model produces robust
and long-lasting thermal and mechanical hypersensitivity, it also produces a variety of
abnormal behavioral and physical effects on animals. This includes nodular lesions on
the ears, feet, tail and genitals, urethritis, diarrhea, as well as eye inflammation.
Additionally, it was reported CFA animals stopped gaining weight at 1 week post CFA
and were barely 50% of their control counterparts weight by the 4th week post-CFA. The
mobility of CFA animals was also affected, with CFA animals rated at mobility scores
that ranged from a score of 0 “animal just lies down” or 1 “animal crawls” for several
weeks post CFA (Calvino et al., 1987). Given the apparently severe systemic side-effects
of this chronic inflammatory pain model, and that most other inflammatory models also
utilize some type of adjuvant with similar side effects, we decided to use a neuropathic
pain model.
There are several well-established and often used models of chronic neuropathic pain
including chronic constriction injury (CCI) of the sciatic nerve, spinal nerve ligation
(SNL) of the L5 or L6 spinal nerve and partial sciatic nerve ligation (PSNL). CCI
involves the loose ligation of the sciatic nerve. This model produces robust mechanical
and thermal hypersensitivity, which can be measured behaviorally, and induces
spontaneous pain behaviors (Bennett et al., 1988). SNL is another commonly used model
that involves tight ligation of the L5 and sometimes L6 afferent spinal nerves that, along
with the efferent L4, merges peripherally to form the sciatic nerve. Behaviorally, this
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model produces hypersensitivity to noxious heat and mechanical hypersensitivity in the
affected foot as well as signs of spontaneous pain (Kim et al., 1992). The PSNL model
involves tightly tying one-third to one half of the sciatic nerve which induces
sympathetically maintained signs of spontaneous pain, touch-evoked hypersensitivity,
and mechanical and thermal hypersensitivity in the surgerized and contralateral foot
(Seltzer et al., 1990).
The chronic constriction injury (CCI) model of neuropathic pain was chosen here because
this model produces robust thermal and mechanical hypersensitivity that has been shown
to last over two months. Additionally, animals exhibit spontaneous pain behaviors such
as guarding the paw, abnormal posture regarding the surgerized limb as well as shaking
and licking of the paw (Bennett et al., 1988), making this model a close correlate to many
of the classic symptoms seen in human chronic neuropathic pain patients. Of the
neuropathic pain models, CCI is the least invasive as it involves only a small incision on
the hindleg as opposed to SNL which require exposure of the spinal column.
Additionally, this technique was previously established in this lab and reproducible
behavioral data had already been generated from it.
Species
We chose to utilize male, Swiss-Webster mice for the studies presented in this
dissertation. The decision to use mice as opposed to rats was due to several reasons. This
laboratory has historically used mice and had already developed a protocol for CCI
surgeries in mice. Additionally, we had planned to look into the genetic component of
CCI and MAP kinases and technology such as shRNA and siRNA are developed for use
in mice as opposed to rats. Lastly, since most research in some of the systems we
examined in response to CCI had previously been conducted in rats, we were interested
in examining potential species differences.
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Conclusion
In conclusion, chronic pain is a debilitating condition which accounts for billions of
dollars in healthcare costs and lost productivity. Due to limited understanding of the
physiological mechanisms involved in the establishment and maintenance of chronic pain
this condition is often difficult to treat. This is especially true for neuropathic pain
conditions which are often resistant to traditional pharmacological treatments. The focus
of this dissertation is to examine the effects of chronic neuropathic pain on three separate
molecular systems known to be involved in regulation and maintenance of chronic pain
states, within the lateral, medial, and descending pain pathways in the mouse.
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Chapter II
General Methodology
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General Methodology
CCI Surgery
The CCI model, adapted from Bennet and Xie (1988), to accommodate the mouse was
used in these studies. Mice were anesthetized under 2.5% isofluorane before having the
lower back and right thigh shaved. The shaved area was then cleansed with 2% povodine
iodine and rinsed with 70% ethyl alcohol. A linear skin incision was made along the
lateral surface of the biceps femoris and tweezers were inserted into the muscle belly to
split the muscle fibers and expose the sciatic nerve. The tips of the tweezers were passed
gently under the sciatic nerve and lifted to pass two 5-0 chromic gut sutures under the
nerve, 1mm apart. The suture was then tied loosely around the nerve and knotted twice
to prevent slippage. The incision was cleansed and the skin was closed with 2–3 ligatures
of 5-0 dermalon. The mice were then allowed to recover on a warmed surface covered
by paper towels. Following recovery, they were returned to their home cage and checked
routinely for 72 hours. A separate control group of sham-operated mice underwent the
exact same surgical procedure with the exception of the ligation of the sciatic nerve.

Hyperalgesia Testing
Thermal hypersensitivity was assessed using a radiant heat source under a plexi-glass
surface applied to the plantar surface of each hindpaw (Hargreaves et al., 1988). For two
days prior to CCI surgery, mice were placed on the plexi-glass floor of the apparatus
(Plantar Test, Ugo Basile, Comerio, Italy) and covered with an inverted clear plastic tube
in order to familiarize the mice with the test. On the day prior to surgery, baseline
measures of paw withdrawal latency were gathered. Mice and rats were allowed to
acclimate on the Plantar Test apparatus for approximately 20 minutes before the start of
the radiant heat test. Five measures of paw-withdrawal latency were conducted with at
least five minutes between each test with the average latency used for statistical purposes.
Mice were again tested for paw-withdrawal latency at either 1, 3, or 10 days post CCI or
sham surgery. Rats were tested at 10 days post-surgery. Paw-withdrawal latencies were
expressed as relative values (%) to baseline latencies for each animal, as well as group
means ± S.E.M. Behavioral data was analyzed via Student’s t-test with differences
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considered statistically significant at p < 0.05. Any CCI mouse or rat that failed to
demonstrate a statistically significant post-CCI withdrawal latency from baseline was
excluded from further analysis.
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Chapter III.
The Effect of Chronic Constriction Injury on the Extracellular
Regulated Kinases
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Introduction
The mitogen-activated protein kinase (MAPK) family has been implicated in recent years
in pain processing and the establishment of chronic pain and this system may be a novel
target for pharmacological treatments. The mammalian MAPK family is a highly
conserved pathway whose functions have been shown to include regulation of gene
expression, inflammation, cell growth and differentiation, apoptosis, and development.
The MAPKs are the endpoint of a three-kinase cascade and are activated via dual
phosphorylation by a MAPK kinase (MEK). MEKs in turn must be activated via dualphosphorylation by a MAPK kinase kinase (MEKK) which is activated by a variety of
extracellular signals (Pearson et al., 2001). While there is some cross-reactivity within
the MAPK cascade subfamilies, most members within an individual cascade are specific
to that cascade and do not react with other MAPK subfamilies. There are many MAPKs
but the most well characterized are the extracellular regulated kinases 1 and 2 (ERK), the
p38 enzymes, and the c-Jun NH2-terminal kinase (JNK) subfamilies (Figure 5).
.
Up to seven types of ERKs have been identified but the most well characterized are ERK
1 and 2. ERK 1 and 2 are 42 and 44 kD proteins with an 83% sequence homology and
due to this are generally studied and referred to together as ERK. ERK proteins are
phosphorylated by MEK 1 and 2 (MEK 1/2) which are activated primarily by the Raf
family of proteins (Roux et al., 2004). A variety of extracellular stimuli have been shown
to activate the ERK cascade including growth factors, viral infection, cytokines, ligands
for G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (Trks) (Johnson
et al., 2002). ERKs have been shown to have many substrates in the membrane, nucleus
as well as the cytoplasm and include phospholipase A2 (PLA2) and the transcription
factors Elk-1, cAMP-response-element-binding-protein (CREB) and c-Fos (Yoon et al.,
2006). These transcription factors then go on to bind to CRE or SRE in gene promoter
regions which activate transcription of both immediate early and late genes.
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Figure 3: Pathway of the MAP Kinase Family of Proteins

Figure 5: The MAP kinase family of proteins by specific pathway. Taken from Ji et al.
(2009).
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The Effect of Chronic Pain on ERK
The chronic constriction injury model (CCI) is a neuropathic pain model that involves the
loose ligation of the sciatic nerve (Bennet and Xie, 1988). This model produces robust
mechanical and thermal hypersensitivity, which can be measured behaviorally, as well as
spontaneous pain behaviors. Using this model in the rat an increase in phosphorylated
ERK (p-ERK) in ipsilateral L4/L5 dorsal root ganglion (DRG) was observed. The time
course showed significant elevations in p-ERK at the third day post-CCI and this
elevation continued to day 14 post-CCI. The relevance of the effects on ERK 1/2 in
relation to the pain hypersensitivity in CCI animals was assessed using a MEK 1/2
inhibitor (MI) . Significant decreases in mechanical hypersensitivity induced by CCI
were observed in MI treated CCI rats (Obata et al., 2004).

Using the spinal nerve ligation (SNL) model, it was found that p-ERK was significantly
increased in L5 dorsal horn ipsilateral to SNL in the rat. This significant increase was
observed from day one until day 21 post-SNL however, the cellular localization of the
elevated levels of p-ERK changed throughout the time course. Ten minutes post SNL
showed significant p-ERK co-localization in L5 dorsal horn neurons while the second
day post-SNL showed p-ERK primarily expressed in microglia which was maintained at
day 10 along with significant co-localization in astrocytes. At day 21, significant p-ERK
activation was seen in only in astrocytes. Significant attenuation of mechanical
hyperalgesia was observed with administration of a MEK 1/2 inhibitor at 2, 10 and 21
days post-SNL (Zhuang et al., 2005).

Significant up regulation of p-ERK was also seen in the injured L5 DRG in the SNL
model, albeit in different populations of DRG neurons (Obata et al., 2004). Changes in
ERK were also observed in another neuropathic pain model, partial sciatic nerve ligation
(PSNL). This model involves tightly tying one-third to one half of the sciatic nerve
which leads to sympathetically maintained signs of spontaneous pain, touch-evoked
hypersensitivity, and mechanical and thermal hypersensitivity in the surgerized and
contralateral foot (Seltzer et al., 1990). Significant up-regulation of p-ERK in the
ipsilateral L4/L5 dorsal horn and nucleus gracilis was observed in PSNL rats when
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compared to contralateral anatomical sites. This up-regulation was seen almost
exclusively in glial astrocytes in both the dorsal horn and nucleus gracilis (Ma et al.,
2002).
In summary p-ERKs have been shown to upregulated in response to chronic neuropathic
pain in the rat. This effect was observed in multiple neuropathic models in the dorsal
horn and DRG. Additionally, the majority of these studies showed the upregulation of
these proteins to be in glial cells as opposed to neurons and blockade of the ERK pathway
caused at least partial attenuation of pain hypersensitivity.

MAPK Regulation of Chronic Pain Induced Cellular and Molecular Changes
The persistent and preferential up-regulation of MAPKs in chronic injury in microglia
and astrocytes, and not in neurons, may seem puzzling because traditional theory has
focused on neuronal sensitization as the major contributor to the establishment and
maintenance of chronic pain. However, new research is showing that glial cells play an
important role in pain states. Microglia and astrocytes have been shown to regulate the
expression of inflammatory cytokines such as IL-1, IL-6 and TNFα as well as COX-2
and reactive oxygen species (ROS) (Banati et al., 1993; Bauer et al., 1997; Lieberman et
al., 1989; Wieseler-Frank et al., 2005). In fact, a study that found significant inhibition of
mechanical hypersensitivity in the spinal cord model of inflammation (SCI) by the
microglial inhibitor minocycline, also found that the drug caused significant decreases in
SCI induced elevated levels of TNFα, IL-1, and IL-10 (Ledeboer et al., 2005).
Interestingly, cytokines like IL-1 and IL-6 as well as TNFα, and COX-2 which are
produced by glia have also been shown to be positively regulated by ERK (Clark et al.,
2003; Koj, 1996). Considering that the same cytokines that are involved in the
production of pain are regulated by MAPKs and inhibition of MAPKs has been shown to
attenuate pain hypersensitivity, MAPKs may play a critical role in the induction and
maintenance of pain.

In addition to affecting the release of cytokines and chemokines, the MAPK pathway has
also been shown to be involved in the regulation of receptors involved in chronic pain.
Cannabinoids have been shown to be effective in relieving chronic pain at the both the
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spinal and supraspinal level (Walker et al., 2005). However, the effect of chronic pain on
the cannabinoid system has yet to be fully elucidated. The upregulation of cannabinoid
receptor type 1 (CB1) has been shown to occur in the thalamus, a major integration center
in pain processing, in response to chronic neuropathic pain (Siegling et al., 2001).
Additionally, CCI caused a significant, time dependent, increase in CB1 protein in the
dorsal horn of the spinal cord compared to sham operated animals. This CCI mediated
increase in CB1 protein was blocked with twice daily administrations of the MEK 1/2
inhibitor, PD98059. This ERK 1/2 mediated blockade of CB1 did not affect the
development of pain hypersensitivity, but rather, blocked the antinociceptive effect of the
potent CB1 agonist WIN 55, 212-2 at a dose that was observed to attenuate both thermal
and mechanical hypersensitivity in CCI rats (Lim et al., 2003). The up-regulation of CB1
in the brain and the spinal cord may play a role in the efficacy of cannabinoid agonists in
attenuating pain behaviors, a theory that has been proposed due to research that found
that cannabinoid agonists not only reversed CCI induced hypersensitivity, but caused
hyposensitivity at doses that did not alter pain perception in non-CCI animals (Herzberg
et al., 1997).

Long Term Potentiation and Pain
Long term potentiation (LTP) is a long lasting enhancement and efficacy of synaptic
transmission following stimulation. It was first characterized over 30 years ago in the
hippocampus (Bliss et al., 1973) and is thought to be a major contributor to synaptic
plasticity in the brain. While the majority of LTP research has focused on its
involvement in the hippocampus with regards to learning and memory, recent research
has shown that LTP is also involved in other CNS structures involved in pain processing
like the spinal cord, amygdala and cerebral cortex. In regards to pain research, the
phenomena of central sensitization, which is increased responsiveness of dorsal horn
nociceptive neurons which outlasts peripheral stimulation (Woolf, 1983) has been
theorized to be a form of LTP. This phenomenon can lead to reductions in threshold of
the nociceptive neurons, increases in receptive field size as the ability of low-threshold
sensory fibers associating with and activating high-threshold nociceptive neurons of the
dorsal horn (Ji et al., 2003) all of which are thought to be involved in the transition of
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acute pain to chronic pain. In support of this theory, a recent study found that high
frequency stimulation (HFS), which is an established method of inducing LTP in vitro
and in animal models, of the cutaneous skin produced both lasting hyperalgesia and
allodynia in humans (Klein et al., 2004).

At the cellular and molecular level, hippocampal LTP and central sensitization share a
great deal of common pathways and mediators. Many of the proteins involved in the
establishment of LTP are regulated by the transcription factors CREB and Elk-1, which
also regulate many of the proteins involved in central sensitization such as prodynorphin,
NK1 and COX-2. Additionally, CREB and Elk-1 are direct targets of MAPK activated
ERK1/2, of which production is upregulated in both hippocampal LTP and central
sensitization. Additionally, a major contributor to establishment of LTP and central
sensitization is the glutamatergic system, which includes NMDA receptors.
ERK 1/2 may indirectly regulate the function of the NMDA receptor via potassium
channels. The voltage-dependent Kv4.2 potassium channel has recently been implicated
in mediating LTP through modulation of NMDA receptor voltage detection (Sweatt,
2004). Additionally, inhibition of A-type K+ current, which is mediated by the Kv4.2
K+ channels, has been shown to increase neuronal excitability, a hallmark of central
sensitization. This has been found in the dorsal horn of the spinal cord and the
hippocampus and this increased excitability has been shown to be mediated in part by
ERK 1/2 (Hu et al., 2003; Yuan et al., 2002). The mechanism by which ERK 1/2
regulates Kv4.2 has been shown to be via direct phosphorylation Kv4.2 channels. Site
directed mutations to mimic phosphorylation of these ERK 1/2 sites in Kv4.2 causes an
increase in the voltage required to activate the channels as well as slower recovery from
inactivation inducing the overall effect of decreased A-type K+ current (Schrader et al.,
2006). Further evidence of Kv4.2 involvement in central sensitization is the localization
of Kv4.2 in the dendrites of excitatory interneurons in lamina II of the dorsal horn, which
is involved in ascending pain pathways (Huang et al., 2005). Behaviorally speaking,
genetic knock-outs (KO) of Kv4.2 were shown to have this same increased neuronal
excitability in the dorsal horn neurons and these KO mice were also observed to have
significantly increased mechanical and thermal hypersensitivity which was mediated in
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part by ERK 1/2(Hu et al., 2006). This evidence points to the involvement of the Kv4.2
receptor, which is meditated by ERK 1/2 in central sensitization of dorsal horn neurons
which has behavioral implications in regards to pain hypersensitivity. In conclusion,
MAPKs play a role in the establishment of the LTP like phenomenon of central
sensitization.

Summary
ERKs have been shown to be upregulated in response to chronic pain. The majority of
these studies showed the upregulation of these proteins to be in glial cells as opposed to
neurons and blockade of one of these pathways caused at least partial attenuation of pain
hypersensitivity induced by nerve injury. Additionally, the MAPK system has multiple
effects on several different receptors such as CB1 and Kv4.2. Therefore, the MAPK
pathway may be a novel target for pharmaceutical or gene therapy in the treatment of
chronic pain. Further research is needed, however, to completely elucidate the role of
this protein kinase family in the initiation and maintenance of chronic pain states. As the
majority of studies have focused on the role of ERK in neuropathic pain states at the level
of the DRG and spinal cord, the focus of this study is to examine the effects of
neuropathic pain on ERK cascades expression and activation in brain areas involved in
the processing and modulation of pain, particularly those sites identified within the
medial and lateral pain pathways.

Materials and Methods
Animals
For all studies male, Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) were
utilized. Mice weighing 25-30g were housed 6 to a cage in animal care quarters on a 12h
light-dark cycle. For the p-ERK ELISA study, male Sprague-Dawley rats weighing 200250g were housed 2 to a cage were also used. Food and water were available ad libitum.
Protocols and procedures were approved by the Institutional Animal Care and Use
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Committee (IACUC) at Virginia Commonwealth University Medical Center and comply
with recommendations of the International Association for the Study of Pain (IASP).

CCI of the Sciatic Nerve
The CCI model, which we adapted from Bennet and Xie (1988), to accommodate the
mouse was used in these studies (described in detail on page 11) . A separate control
group of sham-operated mice and rats underwent an identical surgical procedure with the
exception of the ligation of the sciatic nerve.

Behavioral Testing
Thermal hypersensitivity was assessed using a radiant heat source under a plexi-glass
surface applied to the plantar surface of each hindpaw (Hargreaves et al., 1988). Mice
were again tested for paw-withdrawal latency at either 1, 3, or 10 days post CCI or sham
surgery. Rats were tested at 10 days post-surgery. Paw-withdrawal latencies were
expressed as relative values (%) to baseline latencies for each animal, as well as group
means ± S.E.M. Behavioral data was analyzed via Student’s t-test with differences
considered statistically significant at p < 0.05. CCI mice or rats that failed to demonstrate
statistically significant post-CCI withdrawal latency from baseline were excluded from
further analysis.

RT-PCR Array
At day 10 post-surgery, CCI and sham mice were tested for pain hypersensitivity and
then sacrificed and their PAGs were dissected out. RT2-Profiler MAP Kinase Signaling
Pathway PCR Arrays (SuperArray) which contain 86 MAP kinase pathway genes as well
as housekeeping and control genes were used to assess for changes in the PAG following
CCI surgery. Total RNA was isolated from pooled mouse PAGs (3-4) using a two-step
protocol with TRIzol® Reagent (Invitrogen) followed by additional clean-up with the
Qiagen RNeasy® Mini Kit. RNA concentration and purity was verified using UV
Spectophotometry. cDNA was then reverse transcribed from 1.5µg RNA using RT2 PCR
Array First Strand Kit (SuperArray). cDNA was then added to SYBR Green Master Mix
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(SuperArray) to generate the experimental cocktail and 25µl of this cocktail was added to
each of the 96 wells in the array plate. RT-PCR was then performed.

ERK 1/2 Total Protein Analysis
At day 10 post-surgery, mice were sacrificed and the spinal cord, medulla and
periaqueductal grey (PAG) and thalamus were dissected out and frozen at -80°C until
analysis. Brain regions were sonicated in homogenization buffer (25mM Tris-HCl, 0.5
mM EDTA, 0.5 mM EGTA, 10mM ß-mercaptoethanol, 20mM ß-glycerol, 50 mM
sodium pyrophosphate) and prepared for Western Immunoblotting analysis via SDSPAGE electrophoresis (Bio-Rad Laboratories, Inc., CA). Nitrocellulose blots were
blocked overnight at 4ºC in Tris buffered saline (TBS) with 0.05% Tween-20 plus 1%
BSA solution. Blots were then probed with ERK 1/2 polyclonal antibody (Promega,
Madison, WI) at 1: 5,000 for 2 hours at room temperature followed by horseradish
peroxidase (HRP) secondary staining (Promega) at 1: 5,000 dilution for 1 hour at room
temperature. Protein levels were detected via chemiluminescence (ECL Plus™,
Amersham) and visualized on the Storm 860 Molecular Imager (GMI).

Phosphorylated-ERK 1/2 ELISA
To determine levels of phosphorylated-ERK (p-ERK) the PathScan® Phospho-p44/p42
MAPK Sandwich ELISA Kit (Cell Signaling, Inc, MA) was used. At day 10 post-surgery
mice were euthanized and the spinal cord, medulla, PAG, medial thalamus and anterior
cingulate cortex (ACC) were dissected and flash frozen in liquid nitrogen before storage
at -80°C until further use. On the day of the assay brain regions were homogenized in
Cell Lysis Buffer (Cell Signaling, Inc) that contained a 1% solution of Phosphatase
Inhibitor Cocktail III (Calbiochem, NJ). Protein levels were determined via the Bradford
(1976) assay and 2-7µg/µl of protein were added to each well of the ELISA kit and
incubated overnight at 4ºC. Wells were washed with Wash Buffer and p-ERK antibody
was added to the wells and incubated at 37ºC for 1hr followed by HRP-linked secondary
antibody for 30 min. TMB substrate was then added and wells and absorbance was
measured with a plate reader at 450nm.
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P-ERK Confocal Microscopy
Mice were deeply anesthetized with sodium pentobarbital and perfused with 4%
paraformaldehyde. Brains were removed and allowed to further fix in 4%
paraformaldehyde for 4 hrs and then cryoprotected in a 20% sucrose solution for at least
24 hrs before being stored at -80ºC until further use. On day of assay brains were sliced
on a cryostat at a thickness of 20µM. Brain slices were incubated as free-floating
sections in 5% normal goat serum in PBS + 0.03% Triton X for 1 hr at room temperature.
Slices were then incubated overnight at 4ºC with p-ERK antibody (1:400) (Cell
Signaling, MA) followed by secondary staining with Alexa Fluor 488 (1:400)
(Invitrogen, CA) at room temperature for 2 hrs. Brain slices were then mounted using
Vectashield Soft Set (Vector Laboratories, CA). Slices were imaged via confocal
microscopy using Leica TCS-SP2 AOBS. Images were analyzed for fluorescence using
Image J software and data is expressed as percent of fluorescence per region of interest
(ROI).

Results
Thermal Hyperalgesia Induced by CCI
CCI mice exhibited a 55% decrease in paw withdrawal latency from radiant heat stimulus
in the ipsilateral hindpaw at 10 days post surgery when compared to baseline measures
(t=23.50, p < 0.0001) and a 54% decrease when compared to sham operated controls
(t=19.91, p < 0.0001). CCI rats also showed a significant decrease in paw withdrawal
latency in the ipsilateral hindpaw compared to the contralateral hindpaw (t=20.23, p <
0.0001) (Figure 4).
CCI rats exhibited a 61% decrease in paw withdrawal latency from radiant heat stimulus
in the ipsilateral hindpaw at 10 days post surgery when compared to baseline measures (t
= 4.301, p < 0.01) and a 50% decrease when compared to sham operated controls (t =
4.710, p < 0.01). CCI rats also showed a significant decrease in paw withdrawal latency
in the ipsilateral hindpaw compared to the contralateral hindpaw (t=3.359, p < 0.01)
(Figure 5).
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Figure 4: Comparison of Paw Withdrawal Latency to Radiant
Heat in the Mouse at 10 Days Post Surgery
Comparison of Paw Withdrawal Latency In CCI and Sham Mice
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Figure 4: Effect of CCI on surgery on paw withdrawal latency (s) from a radiant heat
source in Swiss-Webster mice. CCI induced a significant decrease in paw withdrawal
latency when compared to baseline, sham, and contralateral hindpaw measures (***p <
0.0001).
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Figure 5: Comparison of Paw Withdrawal Latency to Radiant
Heat in the Rat at 10 Days Post Surgery
Comparison of Paw Withdrawal Latency In CCI and Sham Rats
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Figure 5: Effect of CCI on surgery on paw withdrawal latency (s) from a radiant heat
source in Sprague-Dawley rats. CCI induced a significant decrease in paw withdrawal
latency when compared to baseline, sham, and contralateral hindpaw measures (n = 4)
(**p < 0.01).
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RT-PCR Array
Since neuropathic pain induced p-ERK upregulation occuring in the DH and DRG has
been shown to play a role in central sensitization we decided to look at the effect of CCI
on the mRNA expression of MAPK genes in the PAG. The PAG is part of the descending
pain pathway and has been shown to have a role in central sensitization following
neuropathy (Suzuki et al., 2005). Of the genes in the PCR Array three genes were
significantly upregulated in the PAGs of CCI mice when compared to sham-operated
controls (Table 1). The three genes that were upregulated were Raf-1, Sfn, and Rb1. Sfn
and Rb1 encode for the stratifin and retinoblastoma 1 proteins, respectively and are both
regulators of the cell cycle. Raf-1 encodes for the MAPK3 protein. MAPK3 proteins are
kinases involved in the phosphorylation and activation of the ERK1/2 cascade. Since pERK has been shown to be implicated in the establishment and maintenance of chronic
pain in the spinal cord (Obata et al., 2004; Zhuang et al., 2005), an investigation of ERK
proteins in the PAG as well as other brain areas involved in the pain pathway was
pursued.

Western Immunoblotting for total ERK
We began our analysis by immunostaining for total protein levels of ERK in the PAG as
well as the spinal cord, medulla and thalamus. There were no significant differences
between CCI and naïve or sham-controls in the Western blotting analysis of total ERK
protein in the spinal cord (p = 0.79), medulla (p = 0.34), (Figure 6) PAG (p = 0.92), and
thalamus (p = 0.52) (Figure 7) when compared by Student’s t-test.

Phospho-ERK ELISA
Previous studies showed that neuropathic pain increased the activity of ERK via
phosphorylation so we decided to examine the effect of CCI on p-ERK levels. There
were no significant differences in levels of phosphorylated ERK 1/2 between CCI and
sham mice at 10 days post surgery in the L4-6 spinal cord (p = 0.06), medulla (p = 0.77),
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Table 1: Increase of mRNA Expression in the PAG of Mice
Following CCI
Gene

Fold Increase

p value

Raf-1

2.53

0.04

Sfn

2.94

0.04

Rb1

2.78

0.004

Table 1: CCI (n = 6) caused a significant increase in mRNA levels of three genes in the
PAG when compared to sham mice (n = 6). Most notably Raf-1,which is an upstream
kinase in the ERK 1/2 cascade, showed a 2.5 fold increase.
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Figure 6: Western Blotting Analysis of Total ERK Protein
Levels
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Figure 6: There were no significant differences in total ERK protein levels in the spinal
cord (n = 4) or medulla (n = 5) of the mouse as detected by Western Immunoblotting.
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Figure 7: Western Blotting Analysis of Total ERK Protein
Levels
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Figure 7: There were no significant differences in total ERK protein levels in the PAG (n
= 5) or thalamus (n = 4) of the mouse as detected by Western Immunoblotting.
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PAG (p = 0.11), medial thalamus (p = 0.41) or ACC (p = 0.59) (Figure 8). Since
significant upregulation in levels of phosphorylated-ERK following neuropathic pain
have been widely reported in the rat, further analysis of the spinal cord was conducted,
this time comparing only tissue from the side of the L4-6 spinal cord ipsilateral to the
surgerized leg and there were no significant differences detected (p = 0.59) (Figure 9).
Since the majority of studies conducted on neuropathic pain and the MAP kinases were in
the rat, we then conducted an analysis of p-ERK in L4-6 spinal cord sections ipsilateral to
the surgerized leg of CCI and sham operated rats and again, there were no significant
differences (p = 0.46) (Figure 9).

P-ERK Confocal Microscopy
We also utilized confocal microscopy to assess for changes in p-ERK levels in the
decending pain pathway structures the PAG and medulla. As determined with the ELISA
assay, there were no significant differences in p-ERK immunofluorescence between CCI
and sham mice in the medulla (p = 0.69) or the PAG (p = 0.94). (Figure 10).

Discussion
CCI induced a 2.5 fold increase in mRNA of the ERK cascade kinase Raf-1 in the PAG
of CCI mice (Table 1). This finding lead us to investigate the effects of CCI on the
protein levels and activity of ERK in PAG. Additionally, we analyzed total ERK
expression and activity in the spinal cord, medulla, and which are part of the lateral pain
pathway, as well as the medial thalamus and ACC, which are part of the medial pain
pathway. Our results did not show any significant differences in ERK levels or activity in
any of those CNS regions in the mouse.
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Figure 8: The Effect of CCI on p-ERK Expression in the
Mouse Brain
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Figure 8: Measures of p-ERK expression were expressed as mean fluorescent intensity ±
S.E.M. CCI did not induce any significant differences in p-ERK expression in the L4-L6
spinal cord (n = 6), medulla (n = 6), PAG (n = 6), ACC (n = 6) or medial thalamus (M.T.)
(n = 5).
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Figure 9: Effect of CCI on p-ERK Expression in the L5/L6
Spinal Cord of Rats and Mice
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Figure 9: Measures of p-ERK expression were expressed as mean fluorescent intensity ±
S.E.M. There were no significant differences in p-ERK expression in ipsilateral L4-6
spinal cord (n = 7) of mice or in the ipsilateral L4-6 spinal cord of rats (n = 4) when
comparing CCI and sham at day 10 post-surgery.
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Figure 10: The Effect of CCI on p-ERK Immunoreactivity in
the Medulla and PAG
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Figure 10: Confocal measures of p-ERK are expressed as percent fluorescence per region
of interest. There are no significant differences in p-ERK staining in the PAG (n = 3) or
medulla (n = 3) when comparing CCI and sham mice at day 10 post-surgery.
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The data which were generated from these studies differs from that of previously
published works in the rat that assessed for changes in MAP kinases in the spinal cord in
response to neuropathic pain. Our CCI mice did not show significant upregulation of pERK expression in the L4/L5 section of their spinal cord. However, to date, there are no
published works utilizing neuropathic pain models in the mouse assessing changes in
ERK in the spinal cord.

Since the majority of published studies on MAPK and chronic pain utilized rats, we
decided to investigate the effects of CCI on p-ERK expression in the ipsilateral L4-6
spinal cord of Sprague-Dawley rats. As determined in the mouse, there were no
significant differences between CCI and sham rats. There are only two published studies
utilizing the CCI model of neuropathic pain in rats which found that there was a
statistically significant increase in lumbar spinal cord levels of p-ERK and those studies
used immunohistochemistry (Song et al., 2005; Tseng et al., 2007) . One of those two
studies also used Western blotting techniques using whole sections of the lumbosacral
spinal cord and while the CCI group showed increases in p-ERK expression across many
different time points, those differences were not reported as statistically significant (Song
et al., 2005). Tseng et al. (2007) conducted an immunohistochemical study using the CCI
model in Sprague Dawley rats which also found significant increases in p-ERK activation
in the dorsal horn ipsilateral to the surgerized leg when compared to the contralateral
dorsal horn. Thus, there are no published papers utilizing CCI that found significant
differences in p-ERK using techniques which require whole tissue dissection as the
ELISA assay we utilized to detect p-ERK expression does. The ELISA assay has not
been previously utilized in any published works on neuropathic pain and MAPK
expression. However, optimization of the ELISA assay in this lab showed it is sensitive
enough to detect linear increases in levels of p-ERK (Figure 11) and the ELISA data
generated in the medulla and PAG of our mice matches the data generated from the
confocal slice staining for p-ERK in the PAG and medulla of mice. CCI has been
reported to have a much greater variability in behavioral outcomes when compared to
other neuropathic pain models (Kim et al., 1997) One reason why we failed to see
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Figure 11: Optimization of p-ERK ELISA Assay
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Figure 11: This ELISA assay shows a linear increase in fluorescence in response to
increased levels of p-ERK protein.
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differences in the levels of p-ERK in the spinal cord of rats is that there seemed to be
much greater variability in the levels of p-ERK expression in the ipsilateral spinal cord
data than that of other brain regions examined with ELISA.

There are published reports of differences in levels p-ERK in the spinal cord of rats
analyzing gross tissue sections, but those studies did not use the CCI model of
neuropathic pain. All neuropathic pain models have different behavioral outcomes and
thus different physiological manifestations. A study conducted comparing SNL and
PSNL models of neuropathic pain and CCI in the rat found similar time courses of
evoked pain responses amongst all three models, but differences in magnitude of those
responses. Additionally, CCI animals showed significantly greater responses to measures
of spontaneous pain than SNL or PSNL rats (Kim et al., 1997). Similar sensitivity
differences were shown again in a comparison of the SNL, PSNL, CCI and two other
models of peripheral nerve injury in the rat (Dowdall et al., 2005). Behavioral differences
were also described in three different neuropathic pain models in the mouse, with CCI
mice showing greater sensitivity to cold allodynia (Walczak et al., 2006). Another study
assessing for physiological changes in response to these three models showed that only in
the SNL model did sympatheic fiber sprouting post injury differ significantly from
controls (Lee et al., 1998). Thus, in these peripheral nerve injury models, which all
involve ligation or transection of the spinal nerves leading to or the sciatic nerve itself,
different behavioral and physiological outcomes are present in rats as well as mice which
could explain the lack of significant differences in p-ERK expression in the spinal cord of
our CCI rats.

In a neuropathic model of digit amputation in the rat immunohistochemical analysis of
the ACC showed a significant increase in p-ERK labeled neurons in the bilateral layers I
and II of the ACC. This increase in p-ERK labeling in the amputation group was also
increased in amputation rats that had, less than 15 minutes prior to sacrifice, been
delivered a noxious stimulus to their amputated hindpaw (Wei et al., 2008). Our study in
CCI mice did not show any significant differences in p-ERK expression in the ACC. The
Wei et. al., (2008) study differed from our own in species as well as pain model, again
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highlighting the differences in physiological outcomes amongst species and models in
pain research.

In conclusion, we have shown that CCI in the mouse produces an upregulation of mRNA
levels of Raf-1 in the PAG, but does not produce changes in ERK protein levels or
activity in the spinal cord, medulla, PAG, thalamus or ACC. Other studies have shown
upregulation of p-ERK in the spinal cord following chronic neuropathic pain but those
studies differed from our own in both species and neuropathic pain model. Thus, our data
sheds doubt on previous data reported with CCI in the rat and warrants a more thorough
investigation of the activity of ERK in this species. We conclude that CCI in the mouse
does not have an effect on levels of ERK or its activity in the brain areas we examined
that have been identified to be involved in the pain pathway.
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Chapter III.
The Effect of CCI on the Cannabinoid System in the Mouse
Brain
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Introduction
The endogenous cannabinoid system is comprised of two distinct receptors, the
cannabinoid receptors 1 (CB1) and 2 (CB2), as well several endocannabinoid lipids
including anandamide and 2-arachydonoyl glycerol. CB1 is expressed primarily in the
central nervous system including many areas involved in nociceptive transmission and
processing including the PAG, anterior cingulate cortex (ACC), amygdala, medial
thalamus MT) as well as the dorsal horn of the spinal cord and dorsal root ganglion of the
rodent (Farquhar-Smith et al., 2000; Glass et al., 1997; Herkenham, 1991; Herkenham et
al., 1991; Hohmann et al., 1999). CB1 receptors are G-protein coupled receptors
(GPCRs) of the Gi/o variety and are primarily localized on the presynaptic terminals of
neurons but not the soma or dendrites (Katona et al., 2001; Katona et al., 2000). The
overall effect of activated Gi/o coupled receptors is inhibition of adenylyl cyclase and
subsequently cyclic AMP, as well as activation of the MAP kinases and inhibition of both
potassium and calcium ion channels. The overall effect appears to be due to cellular
inhibition of the presynaptic terminal which leads to inhibition of neurotransmitter
release.

In contrast to the CB1 receptor, CB2 receptors are localized primarily on immune cells
such as B- and T-lymphocytes, macrophages and organs such as the spleen and thymus
(Pertwee et al., 2002). Like the CB1 receptor the CB2 receptor is coupled to Gi/o proteins
and thus has an overall inhibitory effect. Since CB2 receptors are localized on
inflammatory cytokine producing immune cells it is thought that they may modulate
inflammatory responses involved in pain. In addition to being expressed in the immune
system, CB2 receptors have recently been found to be expressed in several brain regions
involved in the transmission of nociceptive information including the PAG, thalamus and
amygdala (Gong et al., 2006; Onaivi, 2006; Onaivi et al., 2006).

There are five endogenous cannabinoid ligands produced in the central nervous system;
anandamide (AEA), 2-arachydonoyl glycerol (2-AG) and 2-arachydonoyl glyceryl ether
(noladin ether), virodhamine and N-arachydonoyldopamine (NADA). Anandamide
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(AEA) and 2-AG are the most widely studied of the endocannabinoids. AEA and 2-AG
have affinity for both the CB1 and CB2 receptors but AEA has a four-fold greater affinity
for the CB1 receptor (Felder et al., 1995). 2-AG has a lower affinity for the CB1 receptor
than AEA does, but is found in much higher concentrations in the CNS than AEA
(Childers et al., 1998).

The CCI model has been shown to affect the endogenous cannabinoid system within the
CNS. Following CCI, levels of the endocannabinoid lipids, anandamide (AEA) and 2arachidonoylglycerol (2-AG),were shown to have significantly increased in the spinal
cord as well as the dorsal raphe, periaqueductal grey, and rostral ventral medulla (RVM)
(Palazzo et al., 2006); Petrosino et. al. 2007). In respect to the effects of neuropathic pain
on the cannabinoid receptors themselves, at the level of the spinal cord, CCI was shown
to produce a significant upregulation of CB1 protein levels in the ipsilateral dorsal horn
when compared to sham rats (Jones et al., 2004; Wang et al., 2007). Furthermore, CB1
receptors were upregulated in the spinal cord of mice with chronic constriction of the
saphenous nerve (Walczak et al., 2006) and CB1 receptor mRNA has been shown to be
upregulated in the contralateral thalamus in response to transection of the tibial nerve in
the rat (Siegling et al., 2001). This indicates that neuropathic pain in and of itself can
induce changes within the cannabinoid system in a variety of different models and at
differing levels of the CNS. However, few reports have appeared in neuropathic pain on
cannabinoid receptors in mice.

There are a variety of compounds that activate both the CB1 and CB2 receptors. CB1
agonists Delta-9-tetrahydrocannabinol (D9-THC), WIN 55,212-2 and CP 55,940 are
commonly used in research, as are the CB2 selective agonists JWH-133 and GW405833.
Various cannabinoid agonists have been shown to reduce or block behavioral as well as
physiological responses to neuropathic pain models. CCI in the rat invokes increases in
spontaneous firing and noxious evoked heat responses of nociceptive neurons in the
dorsal horn of the spinal cord. These CCI induced changes are blocked via administration
of the cannabinoid agonist WIN 55, 212-2 (Liu et al., 2006). Repeated low dose
administration of WIN 55, 212-2 after CCI has also been shown to reduce hyperalgesia
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while concurrently reducing levels of the inflammatory mediators nitric oxide and
prostaglandin E2 in the rat (Costa et al., 2004). Both the cannabinoid agonists D9-THC
and CP 55,940 are effective in reducing thermal and mechanical hyperalgesia induced by
CCI in the rat (De Vry et al., 2004). Fatty acid amide hydrolase (FAAH) is an enzyme
that cleaves the endocannabinoids anandamide and 2-AG. Reduction of FAAH via
administration of FAAH inhibitors results in an increase in spinal anandamide levels and
decreases hyperalgesia induced by CCI in the rat (Russo et al., 2007).

Intrathecal administration of the CB2 selective agonist JWH-133 in mice with partial
sciatic nerve ligation caused a significant reduction in mechanical allodynia (Yamamoto
et al., 2008). These anti-allodynic effects have also been demonstrated by other CB2
selective agonists such as A-836339 and MDA7 in several different rodent models of
neuropathic pain (Naguib et al., 2008; Yao et al., 2009). The CB2 receptor has also been
implicated in the regulation of neuropathic pain. CCI treated mice lacking the CB2
receptor showed an increase in mechanical as well as thermal hyperalgesia as did CCI
wild-type mice when compared to sham operated controls. However, ligated CB2
knockout mice showed significant levels of hyperalgesia in the contralateral paw when
compared to wild type CCI mice and controls. This hyperalgesia was concurrent with a
bilateral increase in activity of immune cells in the ipsi- and contralateral spinal cords of
CCI CB2 knockout mice and these behavioral and physiological changes were absent in
transgenic CCI mice that over-express the CB2 receptor (Racz et al., 2008). Neuropathic
pain was also shown to cause changes in neurons in the thalamus of spinal nerve ligated
rats. Recordings in the thalamus demonstrated that administration of JWH-133 caused a
significant reduction in spontaneous as well as mechanically induced firing of neurons
which was not observed in sham-operated control rats (Jhaveri et al., 2008).

In human clinical trials cannabinoids have been shown to have limited analgesic potential
in acute pain states yet, in neuropathic pain conditions, cannabinoids have been shown to
be highly potent and in some instances rival the analgesic efficacy of morphine (Ashton
et al., 2008). While most clinical trials involving cannabinoids and neuropathic pain have
focused on subjective pain ratings as reported by patients, one study did assess for the
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effects of cannabinoids on evoked pain responses. Wilsey et al., (2008) reported that
while cannabinoids were effective in reducing pain ratings of neuropathic pain patients,
they were not effective in reducing levels of evoked pain, suggesting a central rather than
a peripheral mechanism. Studies in the animal previously mentioned have found
increases in cannabinoid receptor protein in response to neuropathic pain and we
hypothesize that neuropathic pain also induces increases in CB1 receptor density in the
medial pain pathway which could account for the differences in cannabinoid mediated
analgesia in acute versus chronic pain states.

Materials and Methods
Animals
Male Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) weighing 25-30g were
housed 6 to a cage in animal care quarters on a 12h light-dark cycle. Food and water were
available ad libitum. Protocols and procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) at Virginia Commonwealth University Medical
Center and comply with recommendations of the International Association for the Study
of Pain (IASP).

CCI of the Sciatic Nerve
Surgical technique is described previously (page 11). Briefly, mice were anesthetized
under 2.5% isofluorane before having the lower back and right thigh shaved. Two 5-0
chromic gut sutures were used to loosely ligate the sciatic nerve of the right hindleg. A
separate control group of sham-operated mice underwent the exact same surgical
procedure with the exception of the ligation of the sciatic nerve.

Behavioral Testing
Thermal hypersensitivity was assessed using a radiant heat source under a plexi-glass
surface applied to the plantar surface of each hindpaw (Hargreaves et al., 1988)
(described in detail on page 11). Mice were again tested for paw-withdrawal latency at
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either 1, 3, or 10 days post CCI or sham surgery. Paw-withdrawal latencies were
expressed as relative values (%) to baseline latencies for each animal, as well as group
means ± S.E.M. Behavioral data were analyzed via Student’s t-test with differences
considered statistically significant at p < 0.05. Any CCI mouse that failed to demonstrate
statistically significant post-CCI withdrawal latency from baseline was excluded from
further analysis.
Cannabinoid-Stimulated [35S] GTPγS Binding
On day 1, 3, or 10 post surgery and following thermal hyperalgesia testing, mice were
euthanized, their brains removed and the PAG, medial thalamus and cingulate cortex
were dissected out. Tissue was immediately flash-frozen in liquid nitrogen and stored at 80°C until further processing. On the day of the assay, tissue was thawed and sonicated in
5ml of membrane buffer (50 mM Tris, 3 mM MgCl2, 1 mM EGTA, 100 mM NaCl, pH
7.7). The homogenate was centrifuged at 50,000 x g at 4°C for 10 min and the resulting
pellet was resuspended in 3-5ml of membrane buffer and resonicated. Protein levels were
determined by the Bradford assay (1976) using BSA as a standard. Membranes were then
incubated with 4 mU/ml adenosine deaminase for 35 min at 30°C. Membranes (8-10µg)
were incubated in membrane buffer containing 30 µM GDP, 0.1 nM [35S] GTPγS, and
varying concentrations of the CB1/CB2 agonist WIN 55, 212-2 or the CB2 agonist JWH133. Non-specific binding was assessed via the addition of 20µM unlabeled GTP and
basal levels of binding were assessed via the omission of agonist. Membranes were
incubated for 2h at 30°C with gentle agitation. The incubation was terminated by rapid
filtration under vacuum through Whatman GF/B glass fiber filters, followed by three
washes with ice-cold 50mM Tris, pH 7.2. Bound radioactivity was determined by liquid
scintillation spectrophotometry at 95% efficiency for 35S after extraction of the filters in
4ml Budget Solve scintillation fluid and a 45 min shake cycle.
[3H] SR141716A Binding
Brain membranes were diluted with buffer and prepared under the same conditions as for
the [35S]GTPγS binding assays. Saturation binding analyses were performed by
incubating 10 µg of membrane protein with 0.1–2.5 nM [3H] SR 141716A in the
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presence and absence of 1 mM unlabeled SR141716A to determine nonspecific and
specific binding, respectively. [3H] SR141716A was diluted in assay buffer (50mM Tris,
3mM MgCl2, 1mM EGTA, 0.125% (wt/vol) BSA, pH 7.7) before addition to the assay.
Assays were conducted in duplicate for 1.5 h at 30°C. Reactions were terminated by rapid
filtration under vacuum through Whatman GF/B glass-fiber filters that had been soaked
in Tris buffer, pH 7.4, containing 0.5% (wt/vol) BSA, followed by three washes with the
Tris buffer. Bound radioactivity was determined by liquid scintillation
spectrophotometry after extraction of the filters in 4ml Budget Solve scintillation fluid
and a 45 min shake cycle.

Liquid Chromatography-Mass Spectrometry Analysis (LC/MS)
At day 1 or 10 post surgery, the PAG and ACC were extracted from the brain from each
mouse, weighed and flash frozen in dry ice and stored at -80°C until the time of
processing. On the day of processing, tissues were weighed and homogenized with 1.4 ml
chloroform: methanol (2:1 v/v containing 0.0348g PMFS/ml) after the addition of
internal standards to each sample ( 2 pmole AEA –d8 and 1 nmole 2-AG-d8).
Homogenates were then mixed with 0.3 ml of 0.73% w/v NaCl, vortexed and then
centrifuged for 10 min at 4,000 rpm at 4°C. The aqueous phase plus debris were collected
and extracted again twice with 0.8 ml chloroform. The organic phases from the three
extractions were pooled and the organic solvents were evaporated under nitrogen gas.
Dried samples were reconstituted with 0.1 ml chloroform and mixed with 1 ml cold
acetone. The mixtures were then centrifuged for 5 min at 3000 rpm and 4 °C to
precipitate the proteins. The upper layer of each sample was collected and evaporated
under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed in
autosample vials for analysis.

LC/MS/MS was used to quantify AEA and 2-AG. The mobile phase consisted of (10:90)
water: methanol with 0.1% ammonium acetate and 0.1% formic acid. The column used
was a Discovery  HS C18, 4.6* 15 cm, 3 micron ( Supelco, USA). The mass
spectrometer was run in Electrospray Ionization in positive mode. Ions were analyzed in
multiple reaction monitoring mode and the following transitions were monitored:
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(348>62) and (348>91) for AEA ; ( 356>62) for AEA-d8; (379>287) and(279>269) for
2-AG ; (387>96) for 2AG-d8. A calibration curve was constructed for each assay based
on linear regression using the peak area ratios of the calibrators. The extracted standard
curves ranged from 0.03 pm to 40 pm for AEA and from 0.05nm to
64 nm for 2-AG.

Data Analysis
For [35S]GTPγS binding studies, the percentage of stimulation is expressed as (netstimulated [35S]GTPγS binding/basal) × 100%. Basal binding is defined as specific
[35S]GTPγS binding in the absence of drug and net-stimulated [35S]GTPγS binding is
defined as [35S]GTPγS binding in the presence of drug minus basal. Emax and EC50 values
were calculated from nonlinear regression analysis by fitting of the concentration-effect
curves to the equation E = Emax × agonist concentration /(EC50 + agonist concentration)
using Prism 4.0 software (GraphPad Software Inc., San Diego, CA). For [3H]
SR141716A binding, Bmax and KD values were calculated by fitting of the saturation
curves to the equation B = Bmax × ligand concentration /(KD + ligand concentration) using
Prism 4.0 software (GraphPad Software Inc.). Emax and EC50 and Bmax and KD values were
then analyzed via Student’s t-test to assess for statistical significance between CCI and
sham groups.

Results
Thermal Hyperalgesia Induced by CCI
Sciatic nerve ligation produced a significant reduction in paw withdrawal latency to
thermal stimulus in the ipsilateral paw of CCI mice when compared to baseline measures
and sham-operated controls. Differences were not observed at day 1 but were observed in
the day 3 post-CCI surgery group when compared to baseline (p <0.001, t=11.03) and
sham (t=6.938, p< 0.0001) and also in the day 10 post-CCI group when compared to
baseline (p < 0.0001, t=25.46) and sham mice (p < 0.0001, t=19.35) (Figure 12). Paw
withdrawal latencies were also significantly different in the ipsilateral and contralateral
paws of CCI mice at day 3 (p < 0.01, t=5.193) and day 10 (p <0.0001, t=41.99)-post CCI
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Figure 12: Paw Withdrawal Latency From Radiant Heat
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Figure 12: Sciatic nerve ligation produced a significant reduction in paw withdrawal
latency to thermal stimulus in the ipsilateral paw of CCI mice when compared to
sham control (***p< 0.0001) and baseline (‡ p< 0.0001) measures. This effect
was first observed at Day 3 post-CCI surgery and continued until Day 10.
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surgery (Figure 13). Since differences in withdrawal latencies were greatest at day 10
post-surgery, it was the time point that was selected for all binding experiments, unless
otherwise noted.
Cannabinoid Stimulated [35S] GTPγS Binding
We hypothesized that CCI would induce an increase in both WIN 55, 212-2-stimulated
[35S] GTPγS binding and subsequent receptor density. Binding experiments were
conducted on the membranes of the PAG, medial thalamus and ACC of CCI and sham
operated mice at day 10 post surgery. WIN 55, 212-2 (10-5-10-8 M) produced a
concentration dependent increase in binding in both CCI and sham groups in all brain
areas (Figures 14-16). This efficacy (Emax) of WIN 55, 212-2 was significantly decreased
by 20% in the ACC regions of CCI mice when compared to sham mice (p < 0.01, t =
3.211) (Figure 14). There were no significant differences in Emax values between sham
and CCI mice in the PAG (p= 0.38) (Figure 15) or MT (p= 0.29) (Figure 16) and no
statistically significant differences in EC50 values in any brain areas examined (Table 2).
To further investigate the decrease in Emax values in the ACC a time-course analysis was
conducted assessing WIN 55, 212-2 stimulated [35S] GTPγS binding at days 1 and 3 post
CCI. Further time-course analysis of the ACC region showed that there were no
statistically significant differences in Emax or EC50 observed at day 1 or 3 post surgery
between CCI and sham mice (Figure 17). There were no statistically significant
differences in basal levels of [35S] GTPγS binding in any of the brain areas examined at
any time point which indicates that CCI induced desensitization in WIN 55,212-2stimulated [35S] GTPγS binding are specific to the CB1 receptor and not due to an overall
decrease in the ability of GTP to bind to GPCRs in the ACC.
Additionaly, JWH-133-stimulated [35S] GTPγS binding experiments were conducted in
the PAG and medial thalamus as these two areas have recently been shown to express
functional CB2 receptors (Onaivi et al., 2006). There were not enough CB2 receptors in
these areas of the mouse to generate a binding curve (data not shown), indicating that
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Figure 13: Paw Withdrawal Latency From Radiant Heat By
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Figure 13: Sciatic nerve ligation produced a significant reduction in paw
withdrawal latency to thermal stimulus in the ipsilateral paw of CCI mice
when compared to the contralateral hindpaw. This effect was first
observed at Day 3 post-CCI surgery and continued until Day 10. (**p <
0.01, ***p < 0.0001)
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Figure 14: WIN 55, 212-2 stimulated [35S] GTPγS Binding in
the ACC
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Figure 14: Data is expressed as percent net stimulated binding above basal binding. WIN
55, 212-2-stimulated [35S] GTPγS binding in the ACC shows a significant decrease in
Emax values in CCI mice at day 10 post surgery when compared to sham operated
controls. (n = 8) (** p<0.01)
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Figure 15: WIN 55, 212-2 Stimulated [35S] GTPγS Binding in
the MT
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Figure 15: Data is expressed as percent net stimulated binding above basal binding. There
were no significant differences in WIN 55, 212-2-stimulated [35S] GTPγS binding in the
MT between CCI and sham mice at day 10 post surgery (p > 0.05) (n = 6).
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Figure 16: WIN 55, 212-2 Stimulated [35S] GTPγS Binding in
the PAG
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Figure 16: Data is expressed as percent net stimulated binding above basal binding. There
were no significant differences in WIN 55, 212-2-stimulated [35S] GTPγS binding in the
PAG between CCI and sham mice at day 10 post surgery (p > 0.05) (n = 6).
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Table 2: Emax and EC50 Values from WIN 55, 212-2 Stimulated
[35S] GTPγS Binding

Region

EC50 (µM)
Sham
CCI

Emax (%)
Sham

CCI

PAG

0.192 ± 0.024 0.227 ± 0.031

99.66 ± 4.12

106.6 ± 6.53

M.T

0.170 ± 0.014 0.215 ± 0.088

98.40 ± 5.19

102.8 ± 9.02

ACC

0.130 ± 0.022 0.193 ± 0.038

132.4 ± 6.94

106.3 ± 4.25 **

Table 2: Emax and EC50 values from WIN 55, 212-2-stimulated [35S] GTPγS binding in
brain areas of the mouse brain at day 10-post surgery (**p < 0.01).
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Figure 17: Differences in Means of Emax and EC50 values
Comparing WIN Stimulated [35S] GTPγS Binding in the ACC
by Post-Surgical Day
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Figure 17: Emax and EC50 values are expressed as difference between the group means of
CCI and sham mice. The time course shows that the Emax value of WIN 55, 212-2 was
significantly decreased in CCI relative to sham mice only on day 10 and was not
significantly different day 1 or 3 post surgery. There were no significant differences in
EC50 values at any time point examined (**p < 0.01).
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desensitization shown in the CB1/CB2 agonist WIN 55,212-2-stimulated binding
experiments was due specifically to alterations in CB1 receptor function(s).
[3H] SR141716A Receptor Binding
In order to determine whether the decrease in WIN 55, 212-2 stimulated [35S] GTPγS
binding in the ACC was due to desensitization of the CB1 receptor or a change in the
levels of the CB1 receptor, a tritiated receptor binding experiment was conducted. [3H]
SR 141716A receptor binding was conducted on ACC membranes of mice at day 10 post
CCI surgery. There were no significant differences in Bmax (p= 0.12) or KD (p= 0.22)
values between CCI and sham mice (Figure 18) indicating that the decrease in GTP
binding in the ACC of CCI mice was due to a desensitization of the CB1 receptor and not
a decrease in the number of receptors.

LC/MS Analysis
We used LC/MS to test the hypothesis that the desensitization of CB1 receptors was due
to an increase in the endogenous cannabinoids AEA and 2-AG. There were no significant
differences between CCI and sham mice in endocannabinoids levels measured in the
ACC at either day 1 (p = 0.85 for AEA, p = 0.60 for 2-AG) or day 10 (p = 0.48 for AEA,
p = 0.77 for 2-AG) post surgery. (Figure 19). The PAG was utilized as a control area
since significant differences in endocannabinoid levels were observed in that tissue
following CCI in previous studies (Petrosino et al. 2007). Similarly, there were no
significant differences in endocannabinoid levels in the PAG at either day 1 (p = 0.72 for
AEA, p = 0.13 for 2-AG) or day 10 (p = 0.84 for AEA, p = 0.70 for 2-AG) post surgery
(Figure 20). This indicates that the CCI induced desensitization of the CB1 receptor in
the ACC was not caused by an increase in the endocannabinoids AEA or 2-AG.
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Figure 18: [3H] SR 141716A Receptor Binding in the ACC at
Day 10 Post-Surgery
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Figure 18: [3H] SR 141716A receptor binding was conducted on the ACC at day
10 post CCI surgery. There were no significant differences in CB1 receptor
binding between CCI and sham mice in the ACC (n = 5).
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Figure 19: Levels of AEA and 2-AG in the ACC Following CCI
in Mice
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Figure 19: CCI did not induce significant differences between CCI and sham mice in
levels of the endocannabinoids AEA or 2-AG in the ACC (n = 6).
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Figure 20: Levels of AEA and 2-AG in the PAG Following CCI
in Mice
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Figure 20: CCI did not induce significant differences between CCI and sham mice in
levels of the endocannabinoids AEA or 2-AG in the PAG (n = 6).
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Discussion
The decrease in WIN 55, 212-2 stimulated [35S] GTPγS binding in the ACC coupled with
a lack of differences in the MT was contrary to our hypothesis. Given that previously
mentioned studies have shown an upregulation of CB1 receptor protein in the spinal cord
in response to neuropathic pain, we were anticipating a similar effect in the MT or the
ACC. The decrease in WIN 55,212-2 stimulated [35S] GTPγS binding in the ACC was
without a subsequent decrease in [3H] SR141716A receptor binding, indicating that there
was no change in the overall receptor density, but that the CB1 receptors were
desensitized in response to CCI. Considering that prolonged exposure to the
endocannabinoid, anandamide, has been shown to cause a decrease in [35S] GTPγS
binding in the murine brain (Rubino et al., 2000) and endocannabinoids were shown to be
upregulated in supraspinal areas following CCI (Petrosino et al., 2007) we hypothesized
that there was an increased level of AEA or 2-AG in the ACC following CCI in our mice
to explain the WIN 55, 212-2 stimulated GTPγS binding data. However, our LC/MS
studies did not show any significant differences in levels of 2-AG or AEA in the ACC
between CCI and sham operated mice.

The reason that we did not find any differences in levels of AEA or 2-AG following CCI
surgery may be attributed to the way endocannabinoids are synthesized and degraded.
AEA and 2-AG are not stored in intracellular vesicles like many classic neurotransmitters
but rather are synthesized “on demand” in response to specific stimuli as demonstrated in
several different tissues (Panikashvili et al., 2001), (Basavarajappa et al., 2000), (Stella et
al., 2001). Additionally, both AEA and 2-AG are rapidly internalized and degraded by
the cell following release (Sugiura et al., 2002; Sugiura et al., 2002). Levels of both
anandamide and 2-AG have even been shown have diurnal variation in the rodent
(Valenti et al., 2004), making accurate measurement of concentrations of these lipids
even more difficult.
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Also, there are other endocannabinoids such as N-AEs—Nhomo-clinolenoylethanolamine (HEA) and N-docosatetraenoylethanolamine (DEA) which are
found in brain tissue and have been shown to have nanomolar affinity for the CB1
receptor (Hanus et al., 1993). Therefore, it could be that the desensitization of the CB1
receptor in the ACC of our CCI mice was mediated by an increase in other
endocannabinoids which were not examined.

The PAG is an area in which differences in AEA and 2-AG were previously shown
following CCI (Petrosino et al., 2007) and our data differed from those findings. This
could be due to species difference since the Petrosino (2007) study was conducted in rats
and not mice. There are many behavioral and physiological differences which have been
noted in chronic pain research between these species and in different strains of the same
species. In assessing differences in mechanical hypersensitivity and cold allodynia, it was
found that C57BL/6J mice showed significant differences in response thresholds when
compared to other mouse strains following spared nerve injury of the sciatic nerve (Leo
et al., 2008). These differences in mice have also been reported in a variety of mouse
strains when comparing all types of noxious stimuli, including acute, inflammatory and
neuropathic pain with measured differences in pain tests as great as 54-fold between
strains in some instances (Mogil et al., 1999; Smith et al., 2004) These effects have also
been demonstrated amongst different strains of rats. Among four different rat strains,
significant differences in basal sensitivity to mechanical or heat stimulation were
observed. Following sciatic nerve injury, all strains of rats developed mechanical
allodynia and thermal hyperalgesia however, the time-course and magnitude of the
responses were significantly different even despite the fact that comparable nerve damage
was observed in all the strains. Even more striking is that there were significant
differences between sub-strains of Sprague-Dawley rats with one sub-strain developing
cold allodynia while the other did not and the other sub-strain developing more severe
mechanical allodynia than the other (Xu et al., 2001). These behavioral differences in
nociceptive responses amongst strains also have physiological correlates. An increase in
levels of BDNF following CCI in rats was shown to be greatest in rat strains that
exhibited the most robust hypersensitivity (Herradon et al., 2007). Significant increases in
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prodynorphin in the DRGs of CCI rat strains most resistant to were observed along with
significant decreases in delta-opioid receptors in strains most sensitive to neuropathic
pain ((Herradon et al., 2008)). These studies highlight the differing behavioral and
physiological manifestations that occur amongst species and within strains of the same
species in response to chronic pain and highlight the complexity of the disease itself.

Given the results of our studies, it is likely that the increased analgesic action of
cannabinoids that has been reported to occur in neuropathic pain conditions is due to a
change in a site outside of the ACC, MT or PAG. However, this study shows that CCI of
the sciatic nerve alters the functional activity of the CB1 receptor in the ACC. This study
is the first to show alterations to the cannabinoid system in response to neuropathic pain
within the cortex of the mouse.
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Chapter IV.
The Effect of CCI on the µ-Opioid Receptor in the Mouse
Brain
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Introduction
Opiates are a class of drugs which mimic the effects of the endogenous opioid peptide
ligands, enkephalin, endorphin, and dynorphin within the nervous system. Opiates
activate the opioid receptor subtypes κ, δ, and µ which are highly, yet differentially,
expressed in the central nervous system (Chen et al., 1993; Yasuda et al., 1993).
Morphine and other opiates most commonly prescribed for moderate to severe pain have
the highest efficacy for the µ-opioid receptor. The majority of µ-opioid receptors in the
CNS are localized in the plasma membrane of the cell bodies of neurons as well as on
pre- and postsynaptic terminals (Garzon et al., 2001; Wang et al., 2001). These receptors
are found in significant quantities in peripheral nerve terminals, dorsal horn and dorsal
root ganglion as well as the structures in both the medial and lateral spinothalamic tracts
and limbic system, including the anterior cingulate, insular cortex, medial thalamus and
amygdala (Arvidsson et al., 1995; Ding et al., 1996) and thus are highly involved in the
regulation of nociceptive processing.

The opioid receptors belong to the G-protein coupled family of receptors (GPCR). The µopioid receptor is coupled to the Gαi subtype protein. Activated Gαi receptors inhibit the
function of adenylyl cyclase, which is a regulator of the formation of the second
messenger cyclic AMP. Additionally, N and P/Q type voltage gated Ca++ channels, which
modulate the presynaptic release of glutamate, are inhibited by µ-opioid receptor
activation as are inwardly rectifying K+ channels are activated, which causes a
hyperpolarization of the cell (Pan et al., 2008). Thus, the overall analgesic effect of
opioids could be considered to by via cellular inhibition.

Morphine and other opiates have long been the therapeutic drug of choice in treating
various acute pain conditions. However, in human and animal chronic neuropathic pain
states morphine and other opioids have been shown to have limited analgesic potency and
efficacy (Arner et al., 1988; Ossipov et al., 1995; Przewlocka et al., 1999). Studies have
focused on the potential physiological changes that may contribute to the limited efficacy
of opioids and evidence points to changes that occur at the spinal and supraspinal level.
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At the level of the spinal cord, physiological changes in the µ-opioid system have been
shown to occur in animal models of neuropathic pain. In a model of sciatic nerve
ligation, a downregulation of κ, δ, and µ receptor mRNA was shown in the dorsal root
ganglion, which was not observed in a model of inflammatory pain (Obara et al., 2009).
Other studies have shown an increase in phosphorylation of the µ-opioid receptor in the
dorsal horn of the spinal cord following sciatic nerve ligation (Narita et al., 2004).
Phosphorylation of GPCRs including the µ-opioid receptor is a major mechanism
contributing to the desensitization of the receptor (Kelly et al., 2008). This is evidenced
in a model of alcohol induced neuropathy which resulted in a decrease in the µ-opioid
receptor specific agonist DAMGO stimulated GTPγS binding in the dorsal horn, without
corresponding decreases in µ-opioid receptor protein levels (Narita et al., 2007).
Supraspinally, sciatic nerve ligation in the mouse results in decreases in µ-opioid
stimulated GTPγS binding in both the amygdala and the ventral tegmental area (Narita et
al., 2006; Ozaki et al., 2003), which are two areas in the limbic system known to be
involved in reward as well as the affective component of pain processing.

Both the medial thalamic nuclei (MT) as well as the cingulate cortex (ACC) are part of
the medial pain pathway which is implicated in both chronic as well as the affective
dimension of pain processing (Treede et al., 1999). The medial thalamus has been shown
to be involved in processing of nociceptive information and has multiple connections to
the ACC (Hsu et al., 2000; Kung et al., 2002). Human case studies report that damage to
the medial thalamic nuclei produces chronic pain (Boivie et al., 1989; Montes et al.,
2005) Direct chemical or electrolytic lesion of the rostro-medial, ventro-median, and
parafascicular nuclei of the thalamus was reported to decrease neuropathic pain-like
behaviors in the rat (Saade et al., 2007) and ablation of medial thalamic nuclei alleviates
chronic intractable pain in humans (Jeanmonod et al., 1994; Uematsu et al., 1974; Young
et al., 1995). The ACC has been implicated in pain processing in animal and human
chronic pain states. Electrophysiological as well as imaging studies have shown
activation of the ACC in response to nociceptive stimuli (Kuo et al., 2005; Lorenz et al.,
2005; Sikes et al., 1992; Talbot et al., 1991). Also, lesions of the ACC have been
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demonstrated to reduce chronic pain in humans (Cohen et al., 1999; Foltz et al., 1968;
Hurt et al., 1974). Additionally, the ACC as well as the MT have been shown to be
involved in mu-opioid mediated pain suppression. Morphine injected directly into MT
nuclei has been reported to suppress vocalizations, which are considered to be measures
of the affective component of pain, in response to noxious stimuli (Carr et al., 1988;
Harte et al., 2000; Yeung et al., 1978). fMRI studies in the rat have shown that brain
activation of the ACC induced by noxious stimuli is suppressed in rats following
systemic morphine administration (Chang et al., 2001; Tuor et al., 2000).

The focus of this study is to determine the effect of a chronic neuropathic pain-like state
on the u-opioid receptor in the medial pain pathway, which is known to be involved in
both affective pain processing and u-opioid mediated pain suppression, in order to further
elucidate potential mechanisms of lack of analgesic efficacy of morphine and other
opioids in chronic neuropathic pain states.
.

Materials and Methods
Animals
Male Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) weighing 25-30g were
housed 6 to a cage in animal care quarters on a 12h light-dark cycle. Food and water were
available ad libitum. Protocols and procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) at Virginia Commonwealth University Medical
Center and comply with recommendations of the International Association for the Study
of Pain (IASP).

CCI of the Sciatic Nerve
Surgical technique is described previously (page 11). Briefly, mice were anesthetized
under 2.5% isofluorane before having the lower back and right thigh shaved. Two 5-0
chromic gut sutures were used to loosely ligate the sciatic nerve of the right hindleg. A
separate control group of sham-operated mice underwent the exact same surgical
procedure with the exception of the ligation of the sciatic nerve.
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Behavioral Testing
Thermal hypersensitivity was assessed using a radiant heat source under a plexi-glass
surface applied to the plantar surface of each hindpaw (Hargreaves et al., 1988). Mice
were again tested for paw-withdrawal latency at either 1, 3, or 10 days post CCI or sham
surgery. Paw-withdrawal latencies were expressed as relative values (%) to baseline
latencies for each animal, as well as group means ± S.E.M. Behavioral data were
analyzed via Student’s t-test with differences considered statistically significant at
p < 0.05. Any CCI mouse that failed to demonstrate a statistically significant post-CCI
withdrawal latency from baseline was excluded from further analysis.
Agonist Stimulated [35S] GTPγS Membrane Binding
On the final day of behavioral testing, mice were euthanized, their brains removed and
the PAG, medial thalamus and cingulate cortex were dissected out and weighed for
consistency between samples. Tissue was immediately flash-frozen in liquid nitrogen and
stored at -80°C until further processing. On the day of the assay, tissue was thawed and
sonicated in 5 ml of membrane buffer (50 mM Tris, 3 mM MgCl2, 1 mM EGTA, 100
mM NaCl, pH 7.7). The homogenate was centrifuged at 50,000 x g at 4°C for 10 min and
the resulting pellet was resuspended in 3-5ml of membrane buffer and resonicated.
Protein levels were determined by the Bradford assay (1976) using 1mg/ml BSA as a
standard. Protein was then diluted to reach a standard concentration between all samples.
Membranes were then incubated with 4 mU/ml adenosine deaminase for 35 min at 30°C.
Membranes (8-10µg) were incubated in membrane buffer containing 30 µM GDP, 0.1
nM [35S] GTPγS, and varying concentrations of the µ-opioid agonist [d-Ala2,(NMe)Phe4,Gly5-OH] enkephalin (DAMGO). Non-specific binding was assessed via the
addition of 20µM unlabeled GTP and basal levels of binding were assessed via the
omission of agonist. Membranes were incubated for 2h at 30°C in a water bath with
gentle agitation. The incubation was terminated by rapid filtration under vacuum through
Whatman GF/B glass fibre filters, followed by three washes with ice-cold 50mM Tris,
pH 7.2. Bound radioactivity was determined by liquid scintillation spectrophotometry at
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95% efficiency for 35S after extraction of the filters in 4ml Budget Solve scintillation
fluid and a 45 min shake cycle.
[3H] Naloxone Binding
Membranes from the medial thalamus were diluted with membrane buffer and prepared
under the same conditions as for the [35S]GTPgS binding assays. Saturation binding
analyses were performed by incubating 30 µg of membrane protein with 0.1–7.5 nM
[3H]naloxone in the presence and absence of 1 mM unlabeled naloxone to determine
nonspecific and specific binding, respectively. Assays were conducted in duplicate and
incubated for 1.5 h in 30°C water bath. Reactions were terminated by rapid filtration
under vacuum through Whatman GF/B glass-fiber filters that had been soaked in Tris
buffer, pH 7.4, followed by three washes with ice-cold Tris buffer. Bound radioactivity
was determined by liquid scintillation spectrophotometry after extraction of the filters in
4ml Budget Solve scintillation fluid and a 45 min shake cycle.

Data Analysis
For [35S]GTPγS binding studies, the percentage of stimulation is expressed as (netstimulated [35S]GTPγS binding/basal) × 100%. Basal binding is defined as specific
[35S]GTPγS binding in the absence of drug and net-stimulated [35S]GTPγS binding is
defined as [35S]GTPγS binding in the presence of drug minus basal. Emax and EC50 values
were calculated from nonlinear regression analysis by fitting of the concentration-effect
curves to the equation E = Emax × agonist concentration /(EC50 + agonist concentration)
using Prism 4.0 software (GraphPad Software Inc., San Diego, CA). For [3H]naloxone
binding, Bmax and KD values were calculated by fitting of the saturation curves to the
equation B = Bmax × ligand concentration /(KD + ligand concentration) using Prism 4.0
software (GraphPad Software Inc.). Emax and EC50 and Bmax and KD values were then
analyzed via Student’s t-test to assess for statistical significance between CCI and sham
groups.
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Results
Thermal Hyperalgesia Induced by CCI
Sciatic nerve ligation produced a significant reduction in paw withdrawal latency to
thermal stimulus in the ipsilateral paw of CCI mice when compared to baseline measures
and sham-operated controls. Differences were not observed at day 1 but were observed in
the day 3 post-CCI surgery group when compared to baseline (p <0.001, t=9.079) and
sham (t=6.938, p< 0.0001) and also in the day 10 post-CCI group when compared to
baseline (t=18.27, p < 0.0001) and sham mice (p < 0.001, t=20.32) (Figure 21). Paw
withdrawal latencies were also significantly different in the ipsilateral and contralateral
paws of CCI mice at day 3 (p < 0.01, t=5.193) and day 10 (p <0.0001, t=39.84)-pose CCI
surgery (Figure 22). Since differences in withdrawal latencies were greatest at day 10
post-surgery, it was the time point that was selected for all binding experiments, unless
otherwise noted.
DAMGO Stimulated [35S] GTPγS Membrane Binding
DAMGO stimulated [35S] GTPγS binding was conducted on the membranes prepared
from the PAG, medial thalamus and ACC of CCI and sham operated mice at day 10 post
surgery. The PAG was utilized as a control brain region which is involved in pain
processing, but is outside of the medial pain pathway. DAMGO (10-5-10-8 M) produced
a concentration dependent stimulation of [35S] GTPγS binding in both CCI and sham
groups in all brain areas examined (Figures 23-25). The efficacy (Emax value) of DAMGO
was significantly decreased by 15% in the medial thalamus of CCI mice when compared
to sham mice (t=2.525; p < 0.05) (Figure 23). There were no significant differences in
Emax values between sham and CCI mice in the PAG (p= 0.41) (Figure 24) or ACC (p= 0.
42) (Figure 25) and no statistically significant differences in EC50 values in any brain
areas examined (Table 3).
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Figure 21: Paw Withdrawal Latency From Radiant Heat
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Figure 21: Sciatic nerve ligation produced a significant reduction in paw
withdrawallatency to thermal stimulus in the ipsilateral paw of CCI mice when
compared to sham operated control (*p < 0.0001) and within group baseline
measures (‡p < 0.0001). This effect was first observed at Day 3 post-CCI surgery
and continued until Day 10.
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Figure 22: Withdrawal Latency From Radiant Heat in CCI Mice by
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Figure 22: Sciatic nerve ligation produced a significant reduction in paw
withdrawallatency to thermal stimulus in the ipsilateral paw of CCI mice
when compared to the contralateral paw. This effect was first observed at
Day 3 post-CCI surgery and continued until Day 10 (**p < 0.01, ***p <
0.0001).
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Figure 23: DAMGO Stimulated [35S] GTPγS Binding in the
Medial Thalamus
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Figure 23: Data is expressed as percent net stimulated binding above basal binding. The
efficacy (Emax value) of DAMGO was significantly decreased in the medial thalamus
region in CCI mice on Day 10 in post surgery when compared to sham mice (*p < 0.05)
(n = 6).

71

Figure 24: DAMGO Stimulated [35S] GTPγS Binding in the
PAG
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Figure 24: Data is expressed as percent net stimulated binding above basal binding. CCI
did not induce any significant differences in DAMGO Stimulated GTPγS Binding in the
PAG. (p > 0.05) (n = 6)

72

Figure 25: DAMGO Stimulated [35S] GTPγS Binding in the
ACC
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Figure 25: Data is expressed as percent net stimulated binding above basal binding. CCI
did not induce any significant differences in DAMGO Stimulated GTPγS Binding in the
ACC. (p > 0.05) (n = 5)
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Table 3: Emax and EC50 Values from DAMGO Stimulated [35S]
GTPγS Binding by Brain Area

Region

EC50 (µM)
Sham
CCI

Emax (%)
Sham

CCI

PAG

0.139 ± 0.015 0.124 ± 0.012

139.3 ± 8.17

127.9 ± 3.81

M.T

0.130 ± 0.010 0.132 ± 0.016

127.2 ± 5.01

108.6 ± 5.41*

ACC

0.280 ± 0.069 0.441 ± 0.10

42.74 ± 4.39

39.33 ± 4.36

Table 3: The Emax and EC50 values of DAMGO stimulated [35S] GTPγS binding by brain
area in mice at 10 days post-surgery. (*p<0.05).
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To further investigate the effect of CCI on DAMGO stimulated G-protein activity in the
medial thalamus, a time-course analysis was conducted. The time course showed that the
Emax value of DAMGO was significantly decreased in CCI relative to sham mice only on
day 10 and was not significantly different day 1 or 3 post surgery (Figure 26). This
indicates that the desensitization of the µ-opioid receptor is due an upstream effect. There
were no differences in EC50 values at any time point examined. There were no
statistically significant differences in basal levels of [35S] GTPγS binding in any of the
brain areas examined at any time point which indicates that CCI induced desensitization
in DAMGO-stimulated [35S] GTPγS binding are specific to the µ-opioid receptor and not
due to an overall decrease in the ability of GTP to bind to GPCRs in the medial thalamus.
[3H] Naloxone Receptor Binding
In order to determine whether the decreases in DAMGO stimulated [35S] GTPγS binding
in the medial thalamus were due to a desensitization of the µ-opioid receptor or a
decrease in the overall receptor density, [3H] Naloxone receptor binding was conducted.
In medial thalamus membranes of mice at day 10 post CCI surgery there were no
significant differences in Bmax (p= 0.12) or KD (p= 0.22) values between CCI and sham
mice (Figure 27) indicating that there were no differences in overall µ-opioid receptor
density between CCI and sham mice.

Discussion
Chronic constriction injury of the sciatic nerve produced a significant decrease in
DAMGO stimulated [35S] GTPγS binding in the medial thalamus of mice when compared
to sham operated controls. This effect was seen at day 10 post CCI surgery, but not at
days 1 or 3. The reduction in GTPγS binding in the CCI mice does not appear to be due
to an overall reduction in µ-opioid receptor density, as there were no significant
differences in [3H] DAMGO binding between day 10 post-CCI and sham groups. This
pattern of decrease in µ-opioid receptor function without a decrease in µ-opioid receptor
levels is similar to that reported by Ozaki et al. (2003) and Narita et al. (2006) in the
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Figure 26: Differences in Means of Emax and EC50 values
Comparing DAMGO Stimulated [35S] GTPγS Binding in the
MT by Post-Surgical Day
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Figure 26: Emax and EC50 values are expressed as difference between the group means of
CCI and sham mice. The time course shows that the Emax value of DAMGO was
significantly decreased in CCI relative to sham mice only on day 10 and was not
significantly different day 1 or 3 post surgery. There were no significant differences in
EC50 values at any time point examined.
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Figure 27: [3H] Naloxone Receptor Binding in the MT at Day 10
Post-Surgery
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Figure 27: In medial thalamus membranes of mice at day 10 post CCI surgery there were
no significant differences in Bmax (p= 0.12) or KD (p= 0.22) values between CCI and
sham mice (n = 6).
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amygdala and ventral tegmental area following CCI in the mouse. Both of these brain
areas have been reported to be involved in the affective component of pain processing
(Sotres-Bayon et al., 2001) and morphine directly injected into the amygdala and VTA
has been shown to produce analgesia (Altier et al., 1998; Nandigama et al., 2003). The
lack of significant differences in density in our study as well as the study of Ozaki et al.
(2003) and Narita et al. (2006) is contrary to human imaging studies in chronic pain
patients. PET studies µ-opioid receptor binding demonstrate that µ-opioid receptor
binding decreases in several brain areas including the cortex and medial thalamus in
human peripheral as well as central neuropathic pain patients (Jones et al., 2004;
Maarrawi et al., 2007; Willoch et al., 2004) for at a minimum of 3 months, a time period
considerably longer than that experienced by mice in the CCI model. Thus, it is possible
that neuropathy-induced changes in opioid receptor binding are time dependent.
Moreover, all of these chronic pain patients had, at some point, been given a regimen of
opioid analgesics which may account for the differences in our findings.

There were no significant differences in DAMGO stimulated GTPγS binding in the PAG
which is consistent with other reports of opioid stimulated GTPγS binding in this region
following CCI (Narita et al., 2008). This may indicate that the reduced efficacy of
opioids following chronic neuropathic pain-like state is specific to changes in supraspinal
brain areas involved in the affective component of pain processing rather than pain
modulation.

A potential mechanism to explain the reduced efficacy of opioids in the medial thalamus
of CCI mice could be that there is an increase in endogenous opioid release following
nerve injury that causes desensitization of medial thalamic µ-opioid receptors.
Considering that the reduction in G-protein activation in CCI mice was observed only at
day 10 and not days 3 or 1 post surgery supports this hypothesis. Prolonged acute pain
has been reported to increase levels of ß-endorphin in several brain areas including the
medial thalamus (Porro et al., 1988; Porro et al., 1991) Elevated levels of endomorphin,
another putative endogenous ligand for the mu-opioid receptor, were also observed in the
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rat brain following CCI surgery (Sun et al., 2001). Chronic neuropathic pain was
demonstrated to cause a reduction in tolerance to the pharmacological effect of morphine
and increased phosphorylation of µ-opioid receptors in the striatum of the mouse.
However, in ß-endorphin knockout mice these effects were abolished (Petraschka et al.,
2007). Additionally, Nikkura et al. (2008), reported that sciatic nerve ligation induced a
decrease in DAMGO-stimulated [35S] GTPγS binding in the VTA of wild-type mice but
not in ß-endorphin knockout mice.

In conclusion, we have demonstrated that CCI resulted in decreased µ-opioid receptor
mediated G-protein activation in the medial thalamus of mice, an area which has been
shown to be involved in the affective component of pain processing. This effect was not
due to an overall decrease in µ-opioid receptor density suggesting that the chronic painlike condition produced by CCI resulted in a desensitization of the µ-opioid receptor.
These data coupled with a lack of significant differences in opioid-induced G-protein
activity in the PAG suggests that the reduced analgesic efficacy of opioids in chronic
neuropathic pain may be at least partially attributed to reduced µ-opioid receptor
mediated signaling in the medial thalamus.
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General Discussion
Chronic pain is a significant public health problem. It generates an extraordinary
financial burden to society and inflicts millions with daily suffering that is often
undertreated or resistant to therapeutic interventions. This is due, in part, to our poor
understanding of the pathophysiological mechanisms that underlie the development and
maintenance of chronic pain states. Therefore, strategies directed toward unraveling the
complex biology of chronic pain are of preeminent clinical importance. To this end, the
series of studies presented in this dissertation were designed to examine the effects
chronic neuropathic pain on the expression and function of molecular targets implicated
in the processing and modulation of pain. These studies indicate that chronic
constriction injury of the sciatic nerve in the mouse increases mRNA expression of the
ERK cascade kinase, raf-1 in the PAG which is part of the descending pain pathway and
alters function of the µ-opioid and cannabinoid receptors in different brain areas of the
medial pain pathway

CCI induced a 2.5 fold increase in mRNA of the kinase Raf-1 in the PAG of mice. Raf-1
is part of the ERK cascade in the MAP kinase family of proteins. The PAG is a critical
regulator of nociceptive input and is part of the descending pain pathway. The
descending pain pathway has been shown to have the ability to both inhibit and facilitate
nociceptive transmission and has been implicated in central sensitization, contributing
chronic pain states (Heinricher et al., 2009; Vanegas et al., 2004). Upregulation of MAP
kinases including ERK in the spinal cord have also been implicated in the establishment
and maintenance of central sensitization (Hu et al., 2003). Additionally, pharmacologic
inhibition of MAP kinases has been shown to reduce allodynia and hyperalgesia in
neuropathic pain states, yet MAP kinase inhibitors do not appear to have an effect on
basal levels of pain perception, giving further evidence of their specific role in chronic
pain states (Ji et al., 2007). These data are the first to show a significant increase in
levels of mRNA of a MAP kinase pathway protein in the PAG in response to neuropathic
pain. Given that MAP kinase activation has been shown to contribute to the development
of central sensitization spinal cord, and the PAG can facilitate the development of central
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sensitization in the spinal cord, this upregulation of Raf-1 mRNA may indicate a similar
pro-nociceptive role for MAP kinases in the PAG.

The increase in Raf-1 mRNA in the PAG lead us to investigate the effects of CCI on the
protein levels and activity of ERK in the PAG as well as the spinal cord and medulla,
which are part of the lateral and descending pain pathways, and the medial thalamus and
ACC, which are part of the medial pain pathway. We did not detect any significant
differences in ERK levels or activity in any of those CNS regions in the mouse. Previous
studies have shown an upregulation of p-ERK in the spinal cord of rats using differing
methodology as well as differing pain models. These findings highlight the differences
amongst species as well as individual neuropathic pain models in this field of research.
Species differences in pain research are an issue which has been the subject of ongoing
debate in the field. Differences amongst species and strains amongst the same species
have been found to occur in behavior as well as physiological outcomes in response to
painful states (Max et al., 2008; Mogil, 2009).

Chronic constriction injury of the sciatic nerve produced a significant decrease in
DAMGO stimulated [35S] GTPγS binding in the medial thalamus and WIN 55, 212-2
stimulated [35S] GTPγS binding in the ACC of mice when compared to sham operated
controls. The µ-opioid receptor and the cannabinoid receptor systems have well
established roles in the modulation of nociceptive processing and pain states and these
studies were the first to show a change in µ-opioid and cannabinoid receptor functioning
in the medial pain pathway in response to neuropathic pain. Most animal research on the
establishment and maintenance of chronic pain has been focused on spinal mechanisms
and descending mechanisms that are classically involved in the processing and
modulation of nociceptive input. However, chronic pain is a disease state and recent
human imaging studies have shown that patterns of brain activity differ greatly in human
chronic pain patients when compared to patterns of brain activity in response to acute
pain. These differences are also specific to the disease state or precipitating cause of
chronic pain as patterns of brain activation have been shown to be unique amongst
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differing chronic pain conditions (Apkarian et al., 2005; Baliki et al., 2009; Geha et al.,
2007).

The medial pain pathway is involved in the affective component of pain processing and is
altered in chronic pain states. Several studies conducted in human chronic pain patients
have shown that changes in brain chemistry, activity and receptor density are altered in
the patients in areas in the medial pain pathway such as the prefrontal cortex, cingulate
cortex and thalamus. In some instances these changes in brain chemistry were correlated
to the perceptual quality of pain in patients (de Leeuw et al., 2005; Grachev et al., 2000)
and studies have shown a decrease in opioid receptor binding in the medial pain pathway
of chronic pain patients (Jones et al., 2004; Maarrawi et al., 2007; Willoch et al., 2004).
A limitation of imaging studies in human pain patients is that patients being studied have
been suffering from their ailments for months to years and have undergone in many cases
multiple pharmacological treatments. Animal studies have shown that chronic opioid
treatment can induce desensitization of µ-opioid receptors in multiple brain areas
including the areas involved in nociception (Martini et al., 2007; Sim-Selley et al., 2007).
Thus, it is not entirely possible to determine whether CNS changes in µ-opioid receptor
found in these patients are due to the chronic pain condition itself or to desensitization
and downregulation due to pharmalogical treatment or if chronic pain patients have preexisting differences in µ-opioid receptor levels. The studies presented in this dissertation
show that neuropathic pain itself induces significant desensitization of µ-opioid receptor
in brain areas critical to the regulation and processing of chronic pain states. Opioids
have been shown to have reduced analgesic efficacy in both chronic neuropathic pain
patients and animal models and our data suggest that this could be partially attributed to
the desensitization of the µ-opioid receptor in response to neuropathic pain.

In conclusion, chronic neuropathic pain is hallmarked by extensive physiological changes
throughout CNS, which makes treatment of this disease such a significant challenge. The
data presented in this dissertation demonstrate the ability of a chronic neuropathic pain
like condition to induce significant changes in the mRNA of proteins and activity of
proteins shown to be involved in the establishment or regulation of chronic pain states.
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These changes were observed in three separate supraspinal brain areas involved in either
the descending or medial pain pathways, highlighting the extensive physiological
alterations which occur in response to chronic neuropathic pain. The novel findings
presented in this dissertation provide new areas of investigation for the treatment of this
debilitating disease.
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